Trial reportGene therapy2001
Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial.
Trial report in Gene therapy, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
80 citing papers in PubMed, 243 citations in OpenAlex.
- Human Trial of a Genetically Modified Herpes Simplex Virus for Rapid Detection of Positive Peritoneal Cytology in the Staging of Pancreatic Cancer.EBioMedicine · 2016Trial
- Minimal hepatic toxicity of Onyx-015: spatial restriction of coxsackie-adenoviral receptor in normal liver.Cancer gene therapy · 2007Trial
- Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorin.Cancer gene therapy · 2005Trial
- Effects of febrile temperature on adenoviral infection and replication: implications for viral therapy of cancer.Journal of virology · 2005Trial
- A Phase I Clinical Trial of Intrahepatic Artery Delivery of TG6002 in Combination with Oral 5-Fluorocytosine in Patients with Liver-Dominant Metastatic Colorectal Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- Organoselenium-based Azomethines as Apoptosis Inducers in Colorectal Carcinoma via P53, BAX, Caspase-3, Caspase-6, and Caspase-9 Modulations.Current medicinal chemistry · 2025Article
- Systemic delivery of tannic acid-ferric-masked oncolytic adenovirus reprograms tumor microenvironment for improved therapeutic efficacy in glioblastoma.Cancer gene therapy · 2024Article
- Capsid and Genome Modification Strategies to Reduce the Immunogenicity of Adenoviral Vectors.International journal of molecular sciences · 2021Review
- The Viral Janus: Viruses as Aetiological Agents and Treatment Options in Colorectal Cancer.Frontiers in cellular and infection microbiology · 2020Article
- Polyethylenimine (PEI)-Mediated E1A Increases the Sensitivity of Hepatocellular Carcinoma Cells to Chemotherapy.Medical science monitor basic research · 2019Article
- Suppression of Oncolytic Adenovirus-Mediated Hepatotoxicity by Liver-Specific Inhibition of NF-κB.Molecular therapy oncolytics · 2017Article
- Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer.Cancer immunology, immunotherapy : CII · 2017Review
- Oncolytic Viral Therapy for Mesothelioma.Frontiers in oncology · 2017Review
- Trehalose-Based Block Copolycations Promote Polyplex Stabilization for Lyophilization and in Vivo pDNA Delivery.ACS biomaterials science & engineering · 2016Article
- Article
- Chemovirotherapy: combining chemotherapeutic treatment with oncolytic virotherapy.Oncolytic virotherapy · 2015Review
- Oncolytic viruses in head and neck cancer: a new ray of hope in the management protocol.Annals of medical and health sciences research · 2014Review
- A systematic comparison of the anti-tumoural activity and toxicity of the three Adv-TKs.PloS one · 2014Article
- Adenovirus vectors for gene therapy, vaccination and cancer gene therapy.Current gene therapy · 2013Review
- Enhanced CRAd activity using enhancer motifs driven by a nucleosome positioning sequence.Molecular therapy : the journal of the American Society of Gene Therapy · 2013Article
20 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Both replication-incompetent and replication-selective adenoviruses are being developed for the treatment of cancer and other diseases. Concerns have been raised about the safety of intra-vascular adenovirus administration following a patient death on a clinical trial with a replication-defective adenovirus. In addition, the feasibility of vascular delivery to distant tumors has been questioned. dl1520 (ONYX-015) is a replication-selective adenovirus that has previously shown safety and antitumoral activity following intratumoral injection. This is the first report of intra-vascular administration with a genetically engineered, replication-selective virus. A phase I dose-escalation trial was performed in patients with liver-predominant gastrointestinal carcinoma (n = 11 total; primarily colorectal). dl1520 was infused into the hepatic artery at doses of 2 x 10(8)-2 x 10(1)2 particles for two cycles (days 1 and 8). Subsequent cycles of dl1520 were administered in combination with intravenous 5-fluorouracil (5-FU) and leucovorin. No dose-limiting toxicity, maximally tolerated dose or treatment-emergent clinical hepatotoxicity were identified following dl1520 infusion. Mild to moderate fever, rigors and fatigue were the most common adverse events. Antibody titers increased significantly in all patients. Viral replication was detectable in patients receiving the highest two doses. An objective response was demonstrated in combination with chemotherapy in a patient who was refractory to both 5-FU and dl1520 as single agents. Therefore, hepatic artery infusion of the attenuated adenovirus dl1520 was well-tolerated at doses resulting in infection, replication and chemotherapy-associated antitumoral activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.